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Headache is one of the most common health complaints. According to the Global Burden of Disease 
Study 2013, tension-type headache and migraine are the second and the seventh most prevalent 
chronic disorders in the world (with, respectively, 1.6 billion and 850 million incident cases in 2013) 
[35]. Headache can be associated with substantial morbidity and impaired quality of life [18]. For 
example, migraine is the 6th leading cause of disability worldwide [35].     
There are medications available that effectively alleviate headaches [32], but these may be used 
incorrectly [10; 28]. In particular, both frequent and long-term use of acute headache medication 
may have a paradoxical effect, worsening headaches rather than relieving them. This condition, 
called medication-overuse headache (MOH), is a growing problem, with an estimated prevalence of 
at least 1% in the general population and up to 30-50% in tertiary headache centers [10; 28]. 
Detection of MOH is not easy: many patients rely solely on self-medication with over-the counter 
(OTC) analgesics, and have limited contact with physicians [19]. A study in community pharmacies 
found that about 25% of individuals who purchased OTC analgesics specifically for regular headaches 
overused that acute headache medication, and were thus at risk for developing MOH [27]. 
Community pharmacists may therefore be in a strategic position to identify and advise individuals 
who self-treat, particularly with respect to prevention and early detection of medication overuse 
(MO) in order to avoid development of MOH. To accurately assess the risk of MO, it is important to 
consider a broad profile of patients, as chronic headache is often associated with other pain 
complaints, such as musculoskeletal pain [15; 37]. In fact, there is evidence that the use of analgesics 
for other pain complaints, may also cause MOH in individuals with a primary headache syndrome, 
especially migraine [2; 36]. As yet, there is no clear picture of the types of individuals who self-
medicate their headaches, and the prevalence of MO in these subtypes. This information is necessary 
to develop community pharmacist intervention programs for prevention of MOH. 
This study aimed to identify subgroups of individuals with headache who self-medicate. A 
hierarchical cluster analysis was used to group patients as a function of sociodemographics, pain, 
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disability and medication use for pain. In addition, we compared attitudes about pain medication 







This observational study was carried out from December 2012 till May 2013 in 202 community 
pharmacies in Belgium. Of note, in Belgium, the sale of OTC medicines is limited to pharmacies. 
Therefore, pharmacies are an ideal setting to recruit a representative sample of persons with 
intentions to self-medicate. Approval for the study was granted by the Ethics Committees of Ghent 
University Hospital (for Flanders) and CHU Liege (for Wallonia), and all patients gave written 
informed consent.  
Participants 
Pharmacy customers purchasing an OTC systemic analgesic were approached consecutively by the 
pharmacist and invited to participate in the study (OTC systemic analgesics available in Belgium: 
paracetamol, acetylsalicylic acid, ibuprofen 200-400 mg, naproxen 200 mg, and fixed dose 
combinations of simple analgesics with caffeine). They were eligible when meeting the following 
inclusion criteria: purchasing the analgesic for themselves, being aged ≥18 years, and suffering from 
pain during at least one full day in the last month. From each of the pharmacies, ten patients were 
planned to be recruited.  
For the present analysis, only data of patients with headache were included. A headache patient was 
defined as a patient marking the head on a full body manikin (see section ‘Data collection – pain 
characteristics’). 
Data collection 
Pharmacy customers who agreed to participate completed a self-administered questionnaire, 
developed by the multidisciplinary research team (a neurologist, a pain psychologist, a general 
practitioner, a clinical pharmacologist and pharmacists) on the basis of literature and a previous 
study on this topic [27]. The questionnaire was piloted, before use, by one community pharmacist. It 
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comprised 33 items grouped into five domains: (1) sociodemographics and self-rated health, (2) pain 
characteristics, (3) pain disability, (4) use of pain medication and (5) attitudes about pain medication. 
Sociodemographics and self-rated health 
Respondents reported their gender, age, marital status, employment status and education level. Self-
rated health was measured by the question “How in general would you rate your health?’’ with 
response options of “excellent, very good, good, fair, or poor” [5]. 
Pain characteristics 
Participants were asked to mark the location(s) of their current pain on a full body manikin (front and 
back views; separated into 45 mutually exclusive areas). Respondents also reported whether they 
had a medical diagnosis for their pain complaints. Those without migraine diagnosis completed the 
ID Migraine Screener (ID-M), a valid and reliable screening instrument for migraine in primary care 
[23]. In addition, the questionnaire assessed pain duration and pain frequency (number of days with 
pain in the past 3 months). 
Pain disability  
Disability was assessed by the Von Korff Pain Grading Scale [34]. This 7-item questionnaire measures 
the degree of pain intensity and activity-related disability in the past three months. Six of the items 
are scored on 11-point Likert scales (0 = “no pain/disability” and 10 = “worst pain/total disability”). 
The one remaining item requires filling in the number of days that pain has kept respondents from 
their typical activities. Total scores classify respondents into one of 4 levels of pain intensity and 
activity interference (grade 1: low disability and low pain intensity, grade 2: low disability and high 
pain intensity, grade 3: high disability and moderate limitation of activities, grade 4: high disability 
and severe limitation of activities).  
Use of pain medication 
Respondents reported their current pain medication (OTC and prescribed) with frequency of use 
during the prior three months, and they also indicated the pain location(s) they used the drug for. 
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From the perspective of risk of MOH, MO was defined as overusing acute headache medication in 
terms of treatment days per month (≥10 days/month for ergotamine, triptans, opioids, and 
combination analgesics; ≥15 days/month for paracetamol, acetylsalicylic acid, and NSAIDs) during the 
previous three months, according to the criteria of the International Classification of Headache 
Disorders Third Edition (ICHD-III beta version) for MOH [31]. First, we assessed whether participants 
met the definition of MO for pain medication used for treatment of headache. For patients not 
meeting the definition, we subsequently evaluated whether they met the definition of MO for pain 
medication used to treat their pain at other locations.        
Attitudes about pain medication  
Participants’ attitudes about pain medication were assessed using items from the Pain Medication 
Attitude Questionnaire (PMAQ) [26]. The PMAQ examines concerns held by patients regarding their 
medication use. It consists of 47 items grouped into seven domains (addiction, need, scrutiny, side 
effects, tolerance, mistrust and withdrawal). Each item is scored on a 6-point Likert scale ranging 
from 0 (“never true”) to 5 (“always true”). In this study, we did not use the complete PMAQ but 
selected a number of items that were considered of relevance to our study. This item selection was 
done by a multidisciplinary consensus panel comprising a neurologist (KP), pain psychologist (GC) and 
pharmacist (EM). Firstly, each member of the panel independently selected one or more items from 
each PMAQ domain, based on their own expertise and experience. Secondly, the panel developed a 
consensus on item selection during a face-to-face meeting (psychometric properties of the items 
from the original PMAQ [26] were used to support the discussion). This resulted in a final selection of 
ten PMAQ items which are displayed in Table 2. We grouped the selected items according to the 
domains used in the original PMAQ [26].  
Statistical analysis 
Cluster analysis was performed on complete cases using the following variables:  
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- sociodemographics and self-rated health: sex, age, marital status, employment status, 
education level, and self-rated health (which was considered as a continuous scale ranging 
from 1 (‘excellent’) to 5 (‘poor’)) 
- pain characteristics: presence of migraine (i.e. self-reported physician-diagnosis of migraine), 
number of concomitant pain locations, location of concomitant pain (only pain locations 
present in ≥15% of the study population were included), pain frequency and pain duration 
- pain disability: Von Korff Pain Grading Scale, individual items as well as pain grade (which 
was considered as a continuous scale ranging from 1 to 4) 
- use of pain medication: number, prescription status (only OTC or OTC + prescription 
medication), type (only drug classes used by ≥15% of the study population were included), 
meeting definition of MO for pain medication used for treatment of headache and meeting 
definition of MO for pain medication used for treatment of pain other than headache. 
These variables were subjected to Hierarchical Clustering on Principal Components [17]. We started 
with a factor analysis for mixed data (FAMD) as pre-step before clustering. FAMD balances the 
influence of both continuous and categorical variables and as a consequence, they are compared on 
an equal footing [29]. Next, we performed agglomerative hierarchical clustering on the results of the 
FAMD, using the Euclidean distance, and Ward’s criterion as aggregation criterion. As clusters can be 
difficult to interpret through an eyeball procedure, we used a v-test to characterize them [9]. For 
continuous variables this test investigates whether the mean of the cluster is equal to the mean of 
the total sample. For categorical variables, the v-test evaluates whether a cluster is characterized by 
the categories of the categorical variable.  
One-way ANOVA combined with a Scheffé post hoc test was used to compare mean PMAQ scores 
across the clusters. 
All statistical analyses were performed with R version 2.15.3 (R Development Core Team, Vienna, 




In the 202 participating pharmacies, 10423 patients were contacted and pre-screened, of which 3580 
(34%) matched our inclusion criteria. About 53% (n=1889) of them agreed to participate and were 
included in the main study. More than half of them reported to suffer from headache (N=1107) and 
were thus eligible for inclusion in the present analysis. After exclusion of incomplete cases (N=86), 
we obtained a final sample of 1021 patients (Figure 1). The characteristics of the study population 
are displayed in Table 1 (see column ‘Total sample’).  
Clustering outcome 
Hierarchical clustering was performed on the first two dimensions of the FAMD and suggested three 
patient clusters (Figure 2). Sociodemographics and self-rated health, pain characteristics, disability 
and pain medication use according to cluster are detailed in Table 1. The main features of each 
patient cluster were as follows.  
Cluster 1  
This cluster contained the largest number of participants (n=498, 48.8%). This was the youngest 
group (mean age: 39 years) and included an overrepresentation of highly educated singles, 
employees and students. Individuals in this group were more likely to have a physician-diagnosis of 
migraine. They had a low number of concomitant pain locations and a low pain frequency. This group 
was also characterized by low disability and high pain intensity (pain grade = 2). Overall, individuals in 
this cluster only used OTC analgesics. Medication overusers were less likely in this cluster. 
Cluster 2  
Participants in Cluster 2 (n=301, 29.5%) were the oldest, with a mean age of 59 years. Men, 
married/cohabiting persons, widowers, retired individuals, househusbands/wives and persons with 
lower education levels were more present in this group. Patients had an intermediate number of 
concomitant pain locations, intermediate pain frequency, as well as low disability and high pain 
intensity (pain grade = 2). Individuals only using OTC analgesics (without prescription pain 
9 
 
medication) and users of paracetamol were overrepresented in this group. This cluster also showed a 
slight overrepresentation of persons meeting the definition of MO for analgesics for treatment of 
pain other than headache. 
Cluster 3  
Cluster 3 comprised 21.7% of the total sample (n=222) and had a mean age of 52 years. Individuals in 
this group were more likely to be divorced, unemployed, househusband/housewife or not working 
due to ill health. Also patients with lower levels of education were overrepresented in this cluster. 
Their self-rated health was low. Prevalence of physician-diagnosed migraine was high. They reported 
a high number of concomitant pain locations, high pain frequency, as well as high disability and 
severe limitation of activities (pain grade = 4). Finally, individuals in this group used a high number of 
pain medications, and were more likely to use prescription pain medication in addition to their OTC 
purchased analgesics and to be medication overusers. 
Figure 3 summarizes the key characteristics of the three patient clusters. 
 
Attitudes about pain medication   
Attitudes about pain medication differed significantly between clusters (Table 2). For all but one item 
(i.e., “I would be unwilling to reduce my pain medication(s)”), cluster 3 held significantly higher levels 






This study aimed to identify subgroups of individuals with headache who present to the pharmacy to 
self-medicate. The cluster analysis resulted in the identification of three subgroups, varying 
considerably with respect to sociodemographics, self-rated health, headache type, concomitant pain, 
disability and pain medication use. The clusters can be conveniently characterized as follows: the 
young uncomplicated migraine patient (cluster 1), the older headache patient with some age-related 
concomitant pain (cluster 2) and the middle-aged migraine patient with complex pain comorbidity 
(cluster 3).  
A remarkable difference between the three clusters concerns the extent of pain problems beyond 
headache. Indeed, the number of concomitant pain locations increases from cluster 1 to 2, and from 
2 to 3. The same is true for the frequency of days in pain. It may well be that the pain comorbidity 
contributes to a more frequent analgesic use, and a higher risk for MO. Of further note is that the 
difference between the clusters cannot be easily explained by a simple difference in the duration of 
the pain, or by a simple difference in the age of the participants. Indeed, there was no difference in 
pain duration between the three clusters. Also, age did not vary linearly with the pain complexity of 
the clusters. Cluster 1 had the lowest number of other pain locations, and consisted of the youngest 
individuals. However, cluster 2 consisted of the oldest participants, but had only half the number of 
other pain locations of cluster 3, which is on average 7 years younger.  
The observed prevalence of MO differed substantially between clusters. The first cluster represented 
the largest number of patients and showed the lowest prevalence of MO (16%). These patients were 
relatively young and most of them suffered from migraine. They had the lowest number of other 
pain locations, and their disability was low. These results suggest that this cluster mainly includes 
rather “uncomplicated” migraine patients who seem to be able to self-treat. For these patients, 
evidence-based guidelines on self-medication are available [14].  
Patients from cluster 2 (the older headache patient with some age-related concomitant pain) 
reported a medium prevalence of MO (40%). It seems that this cluster consists of the oldest patients 
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with mainly non-migraine headache, with on average two other pain locations and an overall low 
disability. Intriguingly, in cluster 3 (the middle-aged migraine patient with complex pain comorbidity) 
most patients suffered from migraine, and reported MO (73%), in particular overuse of medication to 
relieve their headaches. These patients also had the highest number of concomitant pain locations, 
and were most disabled by pain. It may well be that this subgroup is particularly at risk of developing 
MOH: they report a high prevalence of migraine (which is a risk factor for MOH [6; 7]) and a high rate 
of MO. Overall, the patients from cluster 3 seem to consist of patients at risk. Indeed, a closer 
examination of their specific profile reveals that it consists of some well-established risk factors for 
chronic pain problems. Patients do report multiple pain problems, which is a well-known risk factor 
for chronic pain [33]. Furthermore, patients have on average a more vulnerable socio-economic 
status. About 30 % of patients were either unemployed, or not working due to ill health, and 15 % of 
the patients were divorced. As yet we do not know what is cause and effect in this patient group. It 
may well be that the relationship between socio-economic status and pain problems is reciprocal, 
potentially fuelling a vicious circle of more pain and suffering. Notwithstanding, guidance and 
treatment of these patients may be more intense than for the patients from other clusters.  
This study also assessed the patients’ concerns regarding their use of pain medications. In line with 
the previous results, patients from cluster 3 displayed the largest concerns about their pain 
medication. They had a higher perceived need for pain medication, were more afraid of being 
prescribed the wrong medication, and had more concerns about unfavorable scrutiny by others, side 
effects, addiction, tolerance and withdrawal. We may easily interpret these concerns as sign of 
addictive behaviour to medication. However, we believe that more is at stake [22]. The worries and 
concerns reported may be better framed within a context of repeated but frustrating attempts to get 
control over their pain and suffering by use of pain medication. As there is no simple solution to their 
problem, patients may start to ruminate and worry about possible solutions [8], and about the pros 
and cons of these possible solutions. A result may be that patients start to self-experiment with pain 
medication, leading to poor adherence, including overuse, underuse or irregular use [26]. Evidently, 
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further research about the reported concerns about pain medication is warranted. A further 
elucidation and specification of these concerns may provide an avenue for interventions. Indeed, 
being concerned about something, is often a reason for seeking help. Being able to recognize and 
address concerns in patients, is a key feature of patient-centered care.  In the context of this study, 
concerns about pain and medication use may be addressed by general practitioners and/or medical 
specialists. However, when community pharmacists have the necessary communication and 
counselling skills, the pharmacy may also prove to be an effective and efficient setting to deliver 
adequate information about headache and its management.   
We argue for an increased role of community pharmacists in the management of headache. To 
prevent MO and limit the risk of developing MOH, a possible recommendation is that pharmacists 
routinely provide advice on the maximum intake frequency of acute headache medication, keep 
records of OTC analgesic dispensing (for headache and other pain conditions), encourage patients to 
report any self-medication to their treating physician, and inform patients about the potential link 
between regular analgesic intake and headache chronification. There is a need for such advice as 
previous research has indicated that most patients are unaware of this association [27]. Moreover, 
this simple advice has proven its effectiveness in both prevention and treatment of MOH in other 
settings, i.e. general practice [21] and hospital [13; 30]. In addition, pharmacists should be vigilant for 
risk factors for pain chronification and could proactively identify and address concerns about pain 
medication, which may help to enhance adherence and detect (fear of) addiction. In case of suspicion 
of MOH, referral to a general practitioner should be made to discuss strategies to reduce the intake 
of acute pain medication including non-drug treatment options [4], preventative drug treatment (e.g. 
for neuropathic pain or migraine) [11; 24] and targeted interventional pain management [25]. 
Increased pharmacist involvement in headache management requires adequate knowledge of 
headache and MOH. Recently, a Swedish study found that current knowledge on MOH is insufficient 
among pharmacy staff [16]. Increased educational efforts about headache disorders will thus be 
necessary to allow pharmacists to take up their extended role. 
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A strength of this study is the large number of participants in a yet largely unstudied patient 
population (i.e. individuals who self-treat their headaches). Another strength is that, to our 
knowledge, this is the first application of cluster analysis to patients with headache in order to 
identify clinically relevant patient subgroups in an unbiased way and not based on any a priori 
assumptions. Some limitations also have to be taken into account when interpreting the results. First, 
the present analysis aimed to be hypothesis-generating and further research is required to confirm 
our findings. Second, this study only screened for MO but we did not make a diagnosis of MOH. It 
should be kept in mind that the current ICHD-criteria for MO are based on expert opinion, rather 
than on formal evidence. However, from a community pharmacist’s point of view, the conceptual 
difficulties in dealing with MO and MOH are not relevant as the pharmacist’s role is to prevent MO in 
order to avoid development of MOH. Third, because we used a body manikin to assess pain 
locations, we were not able to determine whether neck pain reported by migraineurs was a 
concomitant site of pain with the migraine attacks [3; 12; 20] or chronic neck pain as comorbid 
condition [1]. Fourth, we used self-reported data, which may be subject to recall bias (e.g. regarding 
physician diagnosis or medication use). Fifth, the number of potential participants refusing study 
participation was relatively high (47%). Potential bias caused by those who refused participation 
could not be assessed as our Ethics Committee prohibits data collection in study refusers, but we 
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10423 pharmacy customers purchasing 
an OTC systemic analgesic were 
screened for participation 
 6843 did not meet inclusion criteria: 
-  purchased drug not for themselves (N=2585) 
-  aged <18 y (N=368) 
-  not suffering from pain during at least one full   
   day per month (N=3890) 
 
3580 met inclusion criteria 
1691 refused to participate: 
- no time (N=847) 
- no interest (N=565) 
- insufficient knowledge of Dutch or French   
  language (N=96)  
- deprivation of privacy (N=95) 
- other reason (N=88) 
  1889 included 
  1107 reported to suffer from headache 
1021 analyzed 
incomplete cases (N=86) 





Figure 2: Graphical results of the factor analysis for mixed data (FAMD). X and Y axis represent the 
two first dimensions of the FAMD (these two dimensions explain 25.9% of the point variability). 
















































Table 1: Characteristics of the three subgroups of patients identified by cluster analysis. 
 








































































































PAIN CHARACTERISTICS  
Migraine  
Physician-diagnosed 
[Suspected (based on ID-Mb) 
N° of concomitant pain locations 





Pain duration, years 














































PAIN DISABILITY  
Pain Grading Scale, pain gradec 
Pain Grading Scale, individual items 
Pain right now, 0-10 Likert scale 
Worst pain, 0-10 Likert scale 
Average pain, 0-10 Likert scale 
Disability daysd (in past 3 months) 
Daily activities, 0-10 Likert scale 
Social activities, 0-10 Likert scale 





































PAIN MEDICATION  
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N° of pain medications 
Prescription status 
Only OTC pain medication 




Fixed dose combinations of simple analgesics 
with caffeine 
Meeting definition of medication overuse 
For pain medication used to treat headache 






















































Data are presented as mean±SD or % of patients. Bold values: significantly different from the total sample mean (continuous variables) or 
total sample % of patients (categorical variables). Asterisks indicate the level of statistical significance (* P<0.05, ** P<0.01,*** P<0.001). 
a Self-rated health: 1 (‘excellent’), 2 (‘very good’), 3 (‘good’), 4 (‘fair’), 5 (‘poor’). 
b The ID-Migraine Screener (ID-M) was only completed by patients without physician-based migraine diagnosis (N=623). Suspected 
migraine was not included in the cluster analysis (see Methods - statistical analysis). 
c Pain grade: 1 (‘low disability and low pain intensity’), 2 (‘low disability and high pain intensity’), 3 (‘high disability and  moderate limitation 
of activities), 4 (‘high disability and severe limitation of activities’). 
d Days kept from usual activities (work, school or housework)  
e The number of patients meeting the definition of medication overuse for pain medication used to treat other pain was only determined 
for patients not meeting the definition of medication-overuse for pain medication used to treat headache. 




























































“I am concerned that taking medication 













“I would be unwilling to reduce my  
  pain medication(s)” 
“I could cope without my pain 
medication(s)” 
“I feel that I need more pain 
medication(s) than my doctor is giving 


























“I worry what others think about my    











“I have concerns about the side effects 
from my pain medication(s)” 
“I am afraid that I do not know enough 


















“It worries me that I have to increase the 










“I am afraid that I am being prescribed 












“I worry that I will have some 










Data are presented as mean±SD. Each item was answered on a 6-point Likert scale, ranging from 0 (‘‘never true’’) to 5 
(‘‘always true’’).  
a,b Mean values with the same superscript do not differ significantly from each other (Scheffé post hoc test) 
c This item was only answered by patients taking prescription medicines. 
 
 
 
 
 
 
 
 
 
 
 
 
